Early-onset autosomal-recessive parkinsonian-pyramidal syndrome

Acta Neurologica Taiwanica

Volumn 21, Issue 3, 2012, Pages 99-107

  Lai, Hsing Jung ^a   Lin, Chin Hsien ^a   Wu, Ruey Meei ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

ATP13A2; FBXO7; Parkinson's disease; Parkinsonian pyramidal syndrome; PLA2G6

Indexed keywords

LEVODOPA; PARKIN; PARKIN 14; PARKIN 15; PARKIN 9; UNCLASSIFIED DRUG;

AFGHANISTAN; AUTOSOMAL RECESSIVE DISORDER; BABINSKI REFLEX; BRADYKINESIA; BRAIN DISEASE; BRAZIL; CHILE; CHINA; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DISEASE DURATION; DYSKINESIA; DYSTONIA; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HYPERREFLEXIA; INDIA; IRAN; ITALY; JAPAN; MYOCLONUS; ONSET AGE; PAKISTAN; PARKINSON DISEASE; PARKINSONIAN PYRAMIDAL SYNDROME; REVIEW; RIGIDITY; SACCADIC EYE MOVEMENT; TREATMENT RESPONSE; TREMOR; VISUAL HALLUCINATION;

AGE OF ONSET; BLEPHAROSPASM; COGNITION DISORDERS; F-BOX PROTEINS; FAMILY HEALTH; GLOBUS PALLIDUS; GROUP VI PHOSPHOLIPASES A2; HUMANS; MUTATION; PARKINSON DISEASE, SECONDARY; PARKINSONIAN DISORDERS; PHENOTYPE; PROTON-TRANSLOCATING ATPASES;

EID: 84871040502     PISSN: 1028768X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-386. (Pubitemid 46184217)
2. Chen RC, Chang SF, Su CL, Chen TH, Yen MF, Wu HM, Chen ZY, Liou HH. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology 2001;57:1679-1686. (Pubitemid 33055489)
3. Bonifati V. Autosomal recessive parkinsonism. Parkinsonism Relat Disord 2012;18 Suppl 1:S4-S6.
4. Hattori N. Autosomal dominant parkinsonism: its etiologies and differential diagnoses. Parkinsonism Relat Disord 2012;18 Suppl 1:S1-S3.
5. Biernacka JM, Armasu SM, Cunningham JM, Ahlskog JE, Chung SJ, Maraganore DM. Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility? Parkinsonism Relat Disord 2011;17:730-736.
6. Davison C. Pallido-pyramidal disease. J Neuropathol Exp Neurol 1954;13:50-59.
7. Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 1994;89:347-352. (Pubitemid 24163649)
8. Williams DR, Hadeed A, al-Din AS, Wreikat AL, Lees AJ. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 2005;20:1264-1271. (Pubitemid 41645900)
9. Ramirez A, Heimbach A, Gründemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI, Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006;38:1184-1191. (Pubitemid 44470365)
10. Di Fonzo A, Chien HF, Socal M, Giraudo S, Tassorelli C, Iliceto G, Fabbrini G, Marconi R, Fincati E, Abbruzzese G, Marini P, Squitieri F, Horstink MW, Montagna P, Libera AD, Stocchi F, Goldwurm S, Ferreira JJ, Meco G, Martignoni E, Lopiano L, Jardim LB, Oostra BA, Barbosa ER; Italian Parkinson Genetics Network, Bonifati V. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 2007;68:1557-1562. (Pubitemid 46717978)
11. Crosiers D, Ceulemans B, Meeus B, Nuytemans K, Pals P, Van Broeckhoven C, Cras P, Theuns J. Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation. Parkinsonism Relat Disord 2011;17:135-138.
12. Ning YP, Kanai K, Tomiyama H, Li Y, Funayama M, Yoshino H, Sato S, Asahina M, Kuwabara S, Takeda A, Hattori T, Mizuno Y, Hattori N. PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype. Neurology 2008;70:1491-1493. (Pubitemid 351521945)
13. Park JS, Mehta P, Cooper AA, Veivers D, Heimbach A, Stiller B, Kubisch C, Fung VS, Krainc D, Mackay-Sim A, Sue CM. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Hum Mutat 2011;32:956-964.
14. Santoro L, Breedveld GJ, Manganelli F, Iodice R, Pisciotta C, Nolano M, Punzo F, Quarantelli M, Pappatá S, Di Fonzo A, Oostra BA, Bonifati V. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics 2011;12:33-39.
15. Schneider SA, Paisan-Ruiz C, Quinn NP, Lees AJ, Houlden H, Hardy J, Bhatia KP. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 2010;25:979-984.
16. Djarmati A, Hagenah J, Reetz K, Winkler S, Behrens MI, Pawlack H, Lohmann K, Ramirez A, Tadić V, Brüggemann N, Berg D, Siebner HR, Lang AE, Pramstaller PP, Binkofski F, Kostić VS, Volkmann J, Gasser T, Klein C. ATP13A2 variants in early-onset Parkinson's disease patients and controls. Mov Disord 2009;24:2104-2111.
17. Lin CH, Tan EK, Chen ML, Tan LC, Lim HQ, Chen GS, Wu RM. Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore. Neurology 2008;71:1727-1732.
18. Wang L, Guo JF, Nie LL, Zhang HN, Shen L, Jiang H, Pan Q, Xia K, Tang BS, Yan XX. A new variant of the ATP13A2 gene in Chinese patients with early-onset parkinsonism. Chin Med J 2009;122:3082-3085.
19. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007;6:652-662. (Pubitemid 46921058)
20. Usenovic M, Knight AL, Ray A, Wong V, Brown KR, Caldwell GA, Caldwell KA, Stagljar I, Krainc D. Identification of novel ATP13A2 interactors and their role in alpha-synuclein misfolding and toxicity. Hum Mol Genet 2012;21:3785-3794.
21. Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D. Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. J Neurosci 2012;32:4240-4246.
22. Nixon RA, Yang DS, Lee JH. Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 2008;4:590-599.
23. Khateeb S, Flusser H, Ofir R, Shelef I, Narkis G, Vardi G, Shorer Z, Levy R, Galil A, Elbedour K, Birk OS. PLA2G6 mutation underlies infantile neuroaxonal dystrophy. Am J Hum Genet 2006;79:942-948. (Pubitemid 44763408)
24. Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S, Cangul H, Coryell J, Canham N, Nardocci N, Zorzi G, Pasha S, Rodriguez D, Desguerre I, Mubaidin A, Bertini E, Trembath RC, Simonati A, Schanen C, Johnson CA, Levinson B, Woods CG, Wilmot B, Kramer P, Gitschier J, Maher ER, Hayflick SJ. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006;38:752-754. (Pubitemid 43980594)
25. Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, Hardy J, Houlden H, Singleton A, Schneider SA. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009;65:19-23.
26. Shi CH, Tang BS, Wang L, Lv ZY, Wang J, Luo LZ, Shen L, Jiang H, Yan XX, Pan Q, Xia K, Guo JF. PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort. Neurology 2011;77:75-81.
27. Lu CS, Lai SC, Wu RM, Weng YH, Huang CL, Chen RS, Chang HC, Wu-Chou YH, Yeh TH. PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2012;159B:183-191.
28. Sina F, Shojaee S, Elahi E, Paisan-Ruiz C. R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family. Eur J Neurol 2009;16:101-104.
29. Yoshino H, Tomiyama H, Tachibana N, Ogaki K, Li Y, Funayama M, Hashimoto T, Takashima S, Hattori N. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 2010;75:1356-1361.
30. Paisán-Ruiz C, Li A, Schneider SA, Holton JL, Johnson R, Kidd D, Chataway J, Bhatia KP, Lees AJ, Hardy J, Revesz T, Houlden H. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging 2012;33:814-823.
31. Balsinde J, Balboa MA. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. Cell Signal 2005;17:1052-1062. (Pubitemid 40933526)
32. Shojaee S, Sina F, Banihosseini SS, Kazemi MH, Kalhor R, Shahidi GA, Fakhrai-Rad H, Ronaghi M, Elahi E. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am J Hum Genet 2008;82:1375-1384.
33. Zhao T, De Graaff E, Breedveld GJ, Loda A, Severijnen LA, Wouters CH, Verheijen FW, Dekker MC, Montagna P, Willemsen R, Oostra BA, Bonifati V. Loss of nuclear activity of the FBXO7 protein in patients with parkinsonian-pyramidal syndrome (PARK15). PLoS One 2011;6:e16983.
34. Di Fonzo A, Dekker MC, Montagna P, Baruzzi A, Yonova EH, Correia Guedes L, Szczerbinska A, Zhao T, Dubbel-Hulsman LO, Wouters CH, de Graaff E, Oyen WJ, Simons EJ, Breedveld GJ, Oostra BA, Horstink MW, Bonifati V. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 2009;72:240-245.
35. Ho MS, Ou C, Chan YR, Chien CT, Pi H. The utility F-box for protein destruction. Cell Mol Life Sci 2008;65:1977-2000.
36. Paisán-Ruiz C, Guevara R, Federoff M, Hanagasi H, Sina F, Elahi E, Schneider SA, Schwingenschuh P, Bajaj N, Emre M, Singleton AB, Hardy J, Bhatia KP, Brandner S, Lees AJ, Houlden H. Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord 2010;25:1791-1800.